Novo Nordisk adds 2,000 jobs in 2026, shifts to targeted hiring strategy

Novo Nordisk is rebuilding parts of its workforce after a year of significant layoffs, adding around 2,000 employees in 2026 as it sharpens its focus on high-growth areas. The move signals a transition from broad cost-cutting to more targeted talent investment.

The company reduced its headcount by nearly 7,800 roles in 2025—its largest workforce reduction to date. The restructuring was led by CEO Mike Doustdar and aimed at improving efficiency while redirecting resources toward core business segments, particularly its expanding portfolio of diabetes and obesity treatments.

The latest hiring push reflects a more selective approach. Rather than expanding across all functions, Novo Nordisk is focusing on roles aligned with long-term priorities. Recruitment efforts are expected to support production, research, and commercial operations linked to its key therapies.

This dual strategy highlights a broader organisational reset. By reducing roles in some areas while strengthening others, the company is reshaping its workforce to match evolving business needs, while maintaining tighter cost control.

The scale of both layoffs and hiring underscores the depth of change underway. After years of steady workforce expansion, Novo Nordisk appears to be adopting a more flexible model that allows for quicker adjustments in resource allocation.

The shift also reflects a wider trend across the pharmaceutical sector, where companies are reallocating talent toward high-value therapies and innovation-driven functions, while reducing roles in slower-growth segments.